title: Drastic effect of ranibizumab on choroidal neovascularization in idiopathic angioid streaks.
abstract: A 28-year-old man presented with bilateral vision loss. His best-corrected visual acuity (BCVA) was 0.3 in the right eye (OD) and 0.6 in the left eye (OS). Fundoscopy and fluorescein angiography showed angioid streaks encircling the optic discs of both eyes (OU). Spectral Domain Optical Coherence Tomography (SD-OCT) showed bilateral macular serous detachment. Systemic and ocular screening tests showed no specific cause for the angioid streaks. The patient had previously received pegaptanib sodium injection on three occasions, photodynamic therapy in OS, and no treatment in OD. Upon intravitreal injection of ranibizumab (twice in OU), subretinal fluid was nearly eliminated in OU. BCVA increased to 0.6 in OD and 0.9 in OS, and remained improved until 6 months after treatment.
authors.affiliation: Department of Ophthalmology, Siirt Military Hospital, Siirt, TR.
authors.forename: Umit
authors.initials: U
authors.lastname: Yolcu
authors.affiliation: Department of Ophthalmology, Gulhane Military Medical School, Ankara, TR.
authors.forename: Fatih C
authors.initials: FC
authors.lastname: Gundogan
authors.affiliation: Department of Ophthalmology, Gulhane Military Medical School, Ankara, TR.
authors.forename: Oktay
authors.initials: O
authors.lastname: Diner
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000793:Angioid Streaks / Q000150:complications / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab